Pharvaris NV
PHVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.29B
Close$
$5.64
83% downside
Current Fair Value
83% downsideOvervalued by 83% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.29 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | -2.33 |
| Outstanding Shares | 65,305,263 |
Return
| Return on Equity | -71.52% |
|---|---|
| Return on Assets | -65.06% |
| Return on Invested Capital | -72.81% |
Valuation & Multiples
| P/E Ratio | -11.03 |
|---|---|
| PEG | 78.7 |
| Price to Sales | - |
| Price to Book Ratio | 11.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -11.85 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 87,000▲ 19.67% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.60%▲ 4.76% |
|---|---|
| Total Invested | $1.66B▲ 1.61% |
| Investors Holding | 112▲ 4.00% |
ESG Score
No data
About Pharvaris NV
14 employeesPharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alterna...